Avedro adds Apple Tree Partners’ McIntyre to board

Boston-based Avedro Inc, an ophthalmic pharmaceutical and medical device company, has named David J. McIntyre to its board of directors. McIntyre is a partner at Apple Tree Partners.


WALTHAM, Mass.–(BUSINESS WIRE)–Avedro Inc., a Boston-based ophthalmic pharmaceutical and medical device company announces today that David J. McIntyre is joining its Board of Directors. McIntyre currently serves as Partner for Apple Tree Partners, a healthcare venture capital firm where he oversees operations of fund finances and medical device investments.

“I am excited to join the Board at such a pivotal time for the company and look forward to working with the team as Avedro continues to drive its market growth,” said McIntyre.

Prior to Apple Tree Partners, McIntyre served as Executive Vice President, Chief Financial Officer and Chief Operating Officer for HeartWare International, Inc. (NASDAQ: HTWR), where he oversaw the medical device company’s global financial and operational efforts. He previously practiced as a senior attorney specializing in corporate, mergers and acquisitions, and equity capital markets law for both Baker & McKenzie and KPMG. McIntyre has also held various senior financial roles for multinational companies, including Coal & Allied Industries Ltd., a publicly traded subsidiary of Rio Tinto. McIntyre holds an MBA (Fuqua Scholar) from Duke University, a Bachelor of Law from the University of Sydney (Australia) and a Bachelor of Economics in Accounting from the University of Technology, Sydney (Australia). He is also a Certified Practicing Accountant (Australia) and a Legal Practitioner of the Supreme Court of New South Wales.

“Avedro is thrilled to welcome David to the team and I look forward to working with him as we look to expand the global geographic footprint for our corneal cross-linking platform of pharmaceuticals and technologies,” said David Muller, PhD, President and Chief Executive Officer for Avedro.

About Avedro, Inc.
Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross linking and refractive correction.

Avedro distributes its products in various countries outside of the United States through a network of ophthalmic medical device distributors. Avedro’s CE Marked products include capital equipment such as the UV-X devices, the KXL® and KXL II™ Systems, and related proprietary pharmaceuticals such as the VibeX® and MedioCROSS® formulations. These systems and products are used in a variety of treatments including accelerated cross linking for keratoconus, Lasik Xtra® and PiXL™. Avedro’s KXL System and pharmaceuticals are being used in an open-label study involving 83 KXL Systems placed in U.S. clinical sites. Avedro products are not approved for sale in the United States.